The need for real-time monitoring and control has spurred the development of new analytical tools.
Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.
Analytical and functional characterization of virus-like particles enables process reproducibility and product consistency.
Advances in preclinical development play a crucial role in reducing cost for developing biosimilars.